22 Mar

Most Analysts Are Optimistic on Alexion Pharmaceuticals

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 21.63% for Alexion Pharmaceuticals (ALXN) based on the stock’s closing price on March 21.

Analysts first revised the company’s target price downward from $163.06 in January to $161.48 in February and then raised it to $163.24 in March. The current consensus analyst recommendation for the stock is a “buy.”

Most Analysts Are Optimistic on Alexion Pharmaceuticals

Of the 18 analysts covering Alexion Pharmaceuticals, five have given it “strong buys,” ten have given it “buys,” and three have given it “holds.” The highest target price estimate for the company is $188, and the lowest is $125.

On March 21, Alexion Pharmaceuticals closed at $134.21, 1.94% higher than its previous closing price, 45.00% higher than its 52-week low of $92.56, and 4.66% lower than its 52-week high of $140.77. The company’s market cap is $29.497 billion.

Based on its closing price on March 21, Alexion Pharmaceuticals has reported returns of -0.50% in the last week, 3.37% in the last month, and 26.63% in the last quarter. The company has reported returns of 11.08% in the last half year, 11.64% in the last year, and 37.85% year-to-date.

Revenue and EPS estimates

In its fourth quarter, Alexion Pharmaceuticals reported revenue of $1.13 billion, a YoY (year-over-year) rise of 24.08% and $70.06 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $2.14, a YoY rise of 44.59% and $0.30 higher than the consensus estimate.

Analysts expect Alexion Pharmaceuticals’ revenue to see YoY rises of 21.05% to $1.13 billion in the first quarter, 12.24% to $1.17 billion in the second quarter, 18.09% to $1.21 billion in the third quarter, and 10.65% to $1.25 billion in the fourth quarter of 2019. Analysts also expect Alexion’s non-GAAP EPS to see YoY rises of 30.04% to $2.18 in the first quarter, 10.88% to $2.30 in the second quarter, 18.11% to $2.39 in the third quarter, and 12.23% to $2.40 in the fourth quarter.

Analysts expect Alexion Pharmaceuticals’ revenue to see YoY rises of 14.93% to $4.75 billion in 2019, 13.11% to $5.37 billion in 2020, and 7.11% to $5.75 billion in 2021. They expect its non-GAAP EPS to see YoY rises of 17.27% to $9.29 in 2019, 12.98% to $10.49 in 2020, and 9.77% to $11.52 in 2021.

Next, we’ll discuss analysts’ recommendations and projections for Vertex Pharmaceuticals.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.